Webinar Recording
RESONATE-2: Primary and Long-Term Analysis of Ibrutinib Including Dose Modifications for Adverse Reactions
Recorded on: October 16, 2024
RESONATE-2 data reveals how crucial dose modifications are to maintaining the effectiveness of ibrutinib in first-line CLL treatment, especially over the long term.
In this webinar, Marie Sirek, PharmD, BCACP, CPP, from Billings Clinic, walks through key long-term follow-up data and shares strategies for optimizing treatment. Learn how dose modification can help manage adverse reactions, improve outcomes, and enhance patient care.
Presenter: